AI assistant
Guerbet — Earnings Release 2013
Apr 23, 2013
1392_iss_2013-04-23_27c12b46-9f4c-45c6-9da5-226173f17daa.pdf
Earnings Release
Open in viewerOpens in your device viewer
PRESS RELEASE
2013 first-quarter revenue
Villepinte, 23 April 2013
Consolidated Group revenue (IFRS)
| In € thousands |
2012 | 2013 | Change |
|---|---|---|---|
| Total first quarter…………………… | 96,758 | 90,995 | - 6.0% |
Consolidated revenue by region
| In € thousands |
2012 | 2013 | Change |
|---|---|---|---|
| Sales in Europe | 70,617 | 65,383 | - 7.4% |
| Sales in other markets | 26,141 | 25,612 | - 2.0% |
| Total……………………………………… | 96,758 | 90,995 | - 6.0% |
Year's start impacted by the good performance in 2012 H2
Growth in the 2012 second half (+10.9%) that was driven mainly by exceptional sales due to the X-Ray line in Europe slowed momentum for the start of 2013, resulted in a lag in sales of 6% in relation to the first quarter of 2012.
The MRI line contracted 1.3%, notably in response to a decline in reimbursement rates in Switzerland, Belgium and South Korea.
X-Ray product sales were also down (-14.6%), particularly in Europe for the reasons cited above.
Other products in contrast achieved significant gains of 19.3% and in large part attributable to Lipiodol.
Sales trends in the first quarter do not affect the guidance for annual growth of 3% announced at the start of the year.
Contact: CFO Department - Tel.: +33 (0)1 45 91 50 69